secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alpha Cognition Inc. (ACOG)
CIK:        0001655923
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0001213900-24-067814
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alpha Cognition Q2 net loss $2.1M; FDA approves ZUNVEYL for Alzheimer's
-----------------------------------------------------------------------

- Q2 2024 net loss $2.1M ($0.01/share) vs Q2 2023 net loss $2.8M ($0.03/share).
- Cash and equivalents $1.0M at June 30, 2024; no revenue reported.
- R&D expenses $0.9M in Q2, down from $1.3M YoY on trial completion.
- FDA approved ZUNVEYL (benzgalantamine) for mild-to-moderate Alzheimer's disease.
- G&A expenses rose to $1.2M in Q2, including $2.3M shares for services under Spartan Capital agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1655923/000121390024067814/0001213900-24-067814-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1655923/000121390024067814/ea0211011-8k_alpha.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-067814

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer